{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:39:55Z","timestamp":1789875595802,"version":"4.0.1"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T00:00:00Z","timestamp":1264550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2010,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reduced expression of dyskinesia is observed in levodopa\u2010primed MPTP\u2010treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D\u20102\/D\u20103 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug na\u00efve, non\u2010dyskinetic MPTP\u2010treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg\/kg plus carbidopa 12.5 mg\/kg p.o. BID) or pramipexole (0.04\u20130.3 mg\/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125\u20136.25 mg\/kg plus carbidopa 12.5 mg\/kg p.o. BID) and pramipexole (0.1\u20130.2 mg\/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. \u00a9 2010 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.22960","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T17:37:54Z","timestamp":1264613874000},"page":"377-384","source":"Crossref","is-referenced-by-count":27,"title":["Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP\u2010treated common marmosets"],"prefix":"10.1002","volume":"25","author":[{"given":"Kayhan A.","family":"Tayarani\u2010Binazir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Warren","family":"Olanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02697.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100720170062"},{"issue":"2","key":"e_1_2_6_4_2","first-page":"II51","article-title":"The pharmacological therapeutic management of levodopa\u2010induced dyskinesias in patients with Parkinson's disease","volume":"247","author":"Rascol O","year":"2000","journal-title":"J Neurol"},{"key":"e_1_2_6_5_2","first-page":"701","article-title":"Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease","volume":"57","author":"Radad K","year":"2005","journal-title":"Pharmacol Rep"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.035980"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20458"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22052"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01664013"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.32"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100000068"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100037963"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20724"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.suppl_1.S42"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200005000-00002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.10.005"},{"key":"e_1_2_6_18_2","first-page":"537","article-title":"One\u2010year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease","volume":"40","author":"Diamond SG","year":"1984","journal-title":"Adv Neurol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200201000-00001"},{"key":"e_1_2_6_20_2","first-page":"S40","article-title":"[Apomorphine in off state\u2014clinical experience]","volume":"41","author":"Rudzinska M","year":"2007","journal-title":"Neurol Neurochir Pol"},{"key":"e_1_2_6_21_2","first-page":"1297","article-title":"[Apomorphine in treatment of Parkinson's disease with fluctuations]","volume":"33","author":"Zaleska B","year":"1999","journal-title":"Neurol Neurochir Pol"},{"key":"e_1_2_6_22_2","first-page":"1011","article-title":"[Subcutaneous apomorphine infusion in the treatment of Parkinson disease]","volume":"81","author":"Albani C","year":"1992","journal-title":"Schweiz Rundsch Med Prax"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000220818.71231.DF"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2008.01.019"},{"key":"e_1_2_6_25_2","first-page":"1085","article-title":"[Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?]","volume":"32","author":"Catalan\u2010Alonso MJ","year":"2001","journal-title":"Rev Neurol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.1.14"},{"key":"e_1_2_6_27_2","first-page":"39","article-title":"Optimization of levodopa therapy","volume":"42","author":"Pfeiffer R","year":"1992","journal-title":"Neurology"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2004.07.015"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110203"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.10.005"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2004.07.015"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200005000-00002"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.61.6_suppl_3.S12"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00001"},{"key":"e_1_2_6_36_2","first-page":"S90","article-title":"Factors influencing the onset and persistence of dyskinesia in MPTP\u2010treated primates","volume":"47","author":"Jenner P","year":"2000","journal-title":"Ann Neurol"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22596"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02211.x"},{"key":"e_1_2_6_39_2","first-page":"35","article-title":"Chronic s.c. lisuride in Parkinson's disease\u2014motor\u2010performance and avoidance of psychiatric side effects","volume":"27","author":"Bittkau S","year":"1988","journal-title":"J Neural Transm Suppl"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320611"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410140213"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110319"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22960","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22960","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:23:08Z","timestamp":1760962988000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,15]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,2,15]]}},"alternative-id":["10.1002\/mds.22960"],"URL":"https:\/\/doi.org\/10.1002\/mds.22960","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,15]]}}}